San Diego-based Illumina Inc. has partnered with Wuhan, China-based Kindstar Global to expand Illumina’s genetic testing services to more than 3,300 hospitals across China.

Kindstar Global provides diagnostic testing services to hospitals throughout China. Illumina is a local developer and manufacturer of life sciences tools, and holds a large volume of cutting-edge genetic sequencing technology. The publicly traded company has a market capitalization of about $7 billion.

“Kindstar’s adoption of Illumina’s TruSight technology across its extensive network in China speaks to the breadth and depth of content in this innovative portfolio,” said Matt Posard, senior vice president and general manager of Illumina’s Translational and Consumer Genomics business.

— SDBJ Staff Report